Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
The new research might make self-injection of this antiretroviral therapy (ART) a more feasible option. But the study published in Clinical Infectious Diseases by scientists at GSK and ViiV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback